University of California San Francisco

Amrita Basu, PhD

Amrita Basu large
Amrita Basu, PhD

Associate Professor of Surgery
Division of Surgical Oncology

Address

550 16th Street, #6355
San Francisco, CA 94158
United States

Email: [email protected]

Education

Institution Degree Dept or School End Date
Broad Institute of Harvard and MIT Postdoctoral Fellow Computational Chemical Biology
Cornell University B.S. Electrical Engineering
Rockefeller University, Tri-Institutional Computational Biology Program Ph.D. Computational Biology

Awards & Honors

Award Conferred By Date
Chan Zuckerberg Biohub Awardee 2026/2029
Burroughs Wellcome Fund Innovation in Regulatory Science Award 2021/2026
Interstellar Award (New York Academy of Sciences/Japan Center for Medical Research and Development) 2019/2020
White House Presidential Innovation Fellow 2016/2017
Sage Bionetworks Young Investigator Award 2013

Grants and Funding

  • Implementation of ePROs Monitoring During Cancer Treatment at UCSF Health System | PCORI | 2026-07-01 - 2030-07-01 | Role: Co-Principal Investigator
  • Analyzing Patient-level Data in a Breast Cancer Clinical Trial | NCI | 2023-07-19 - 2028-07-19 | Role: Principal Investigator
  • Integrated Organoid Systems for Immunotherapy Toxicity | Chan Zuckerberg Biohub Initiative | 2026-04-01 - 2028-04-01 | Role: Co-Principal Investigator
  • Developing a Toxicity Framework using Patient-Reported Outcome | The Burroughs Wellcome Fund | 2021-09-01 - 2026-09-17 | Role: Principal Investigator
  • Predicting the Likelihood of Immune-related Adverse Events in Breast Cancer Patients | NIH | 2021-09-15 - 2023-08-31 | Role: Principal Investigator
  • NIH | 2017-09-08 - 2022-08-31 | Role: Co-Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.
    Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R| | PubMed
  2. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L| | PubMed
  3. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, Hershman DL, Basu A| | PubMed
  4. The "PRO"mise and "PRO"gress of PROs in cancer clinical trials.
    Basu A, Hershman DL| | PubMed
  5. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  6. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.
    Umashankar S, Basu A, Esserman L, Van't Veer L, Melisko ME| | PubMed
  7. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM| | PubMed
  8. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M| | PubMed
  9. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A| | PubMed
  10. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed